4 Topic Commentaries

FDA approves once-weekly insulin for type 2 diabetes

• 

  Ingrid N. Chapman, Pharm.D., BCPS

  Risk management / pharmacy

  •

  U.S. Food and Drug Administration (FDA)

  The observed risks of insulin icodec are monitorable and manageable and do not outweigh the demonstrated benefits.

  Source
• 

  Jayabharathi Vaidyanathan, PhD

  Clinical pharmacology

  •

  U.S. Food and Drug Administration (FDA)

  For T2D patients, there was no significant increase in risk of hypoglycemia with insulin icodec relative to a daily basal comparator.

  Source
• 

  Patrick Archdeacon, MD

  Endocrinology / diabetes (regulatory)

  •

  U.S. Food and Drug Administration (FDA)

  There is an unmet need for new insulin options that can reduce insulin treatment burden, improve adherence, and contribute to improved glycemic control.

  Source
• 

  Christopher W. Goodman, MD

  Endocrinology

  •

  New England Journal of Medicine

  Fewer injections might be appealing to patients, but management dilemmas seem likely.

  Source